Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LIGAND PHARMACEUTICALS INC Director's Dealing 2017

Mar 4, 2017

31289_dirs_2017-03-03_41695541-9d24-4b07-9033-263933bc5fb5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2017-03-02

Reporting Person: FOEHR MATTHEW W (President and COO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-03-02 Common Stock M 6879 $9.97 Acquired 97599 Direct
2017-03-02 Common Stock S 6879 $103.3891 Disposed 90720 Direct
2017-03-03 Common Stock M 2000 $9.97 Acquired 92720 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-03-02 Employee Stock Option (right to buy) $9.97 M 6879 Disposed 2021-04-18 Common Stock (6879) Direct
2017-03-03 Employee Stock Option (right to buy) $9.97 M 2000 Disposed 2021-04-18 Common Stock (2000) Direct

Footnotes

F1: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.